Is InflaRx N.V. (IFRX) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 1.2% / 30% | 80.4% / 30% | 2.6% / 30% | 1928.24% / 5% | ✗ NOT HALAL |
| DJIM | 1.2% / 33% | 80.4% / 33% | 2.6% / 33% | 1928.24% / 5% | ✗ NOT HALAL |
| MSCI | 1.1% / 33% | 69.5% / 33% | 2.3% / 33% | 1928.24% / 5% | ✗ NOT HALAL |
| S&P | 1.2% / 33% | 80.4% / 33% | 2.6% / 33% | 1928.24% / 5% | ✗ NOT HALAL |
| FTSE | 1.1% / 33% | 69.5% / 33% | 2.3% / 50% | 1928.24% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 37898.3% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -88.6% | |
| Return on Assets (ROA) | -46.0% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$49M |
| Free Cash Flow | -$49M |
| Total Debt | $805,086 |
| Debt-to-Equity | 2.2 |
| Current Ratio | 4.1 |
| Total Assets | $76M |
Price & Trading
| Last Close | $0.93 |
| 50-Day MA | $0.92 |
| 200-Day MA | $1.07 |
| Avg Volume | 457K |
| Beta | 1.5 |
|
52-Week Range
$0.71
| |
About InflaRx N.V. (IFRX)
InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a a first-in-class monoclonal anti-human complement factor C5a antibody, which is in Phase 3 clinical trial for the treatment for patients suffering from early septic organ dysfunction, biological proof of concept was established, demonstrating its unique C5a blocking ability and selectivity; Izicopan, an oral, low molecular weight drug to target C5aR with high affinity and selectivity has completed completing Phase 2a trials; and IFX002, an advancement of vilobelimab technology, which is in preclinical development for the treatment of chronic inflammatory indications. It has co-development agreement with Staidson (Beijing) BioPharmaceuticals Co., Ltd.; Cell line sales agreement with Catalent Pharma Solutions LLC; Clinical Trial Collaboration Agreement with the U.S. DHHSs, Administration for Strategic Preparedness and Response (ASPR), BARDA and PPD Development, L.P., or PPD. InflaRx N.V. was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. The company was founded in 2007 and is headquartered in Jena, Germany.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is InflaRx N.V. (IFRX) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), InflaRx N.V. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is InflaRx N.V.'s debt ratio?
InflaRx N.V.'s debt ratio is 1.2% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.1%.
What are InflaRx N.V.'s key financial metrics?
InflaRx N.V. has a market capitalization of $66M, and revenue of $165,789. Return on equity stands at -88.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.